PET imaging of solid tumors with a CD147-targeting probe
Treatments studied
Part of Cancer clinical trials.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer.
- You are between 18 and 75 years old.
- You are able to care for yourself and can walk without help (ECOG score 0 or 1).
- You have at least one tumor that can be safely biopsied (sample taken) before or after the PET scan.
- Your recent blood counts and liver/kidney tests are within acceptable limits.
- You agree to use birth control during the study and for 6 months after (for both men and women).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that targets a protein called CD147, which is found on many solid tumors. The goal is to see if this agent can help doctors better stage your cancer using a PET/CT scan.
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
This trial studies whether a special PET scan probe that targets CLDN18.2 can help show solid tumors in the body. If you have a solid tumor that can be measured on scan, you may be invited to have imaging with the probe.
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
This trial tests how well a special PET/CT scan with a radioactive tracer called F18 FBPA can detect different types of solid tumors. It aims to see if this scan is safe and effective at finding tumors.
This trial tests a new imaging agent that targets a protein called B7-H3 found on many solid tumors. It uses PET/CT to help doctors see and stage tumors more clearly.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.